You just read:

DelMar Pharmaceuticals [Nasdaq:DMPI] Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors

News provided by

DelMar Pharmaceuticals, Inc.

Feb 19, 2020, 08:00 ET